Jane Street Group LLC Has $1.12 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jane Street Group LLC decreased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 29.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,173 shares of the company’s stock after selling 146,934 shares during the quarter. Jane Street Group LLC owned approximately 0.50% of Amylyx Pharmaceuticals worth $1,115,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AMLX. Allspring Global Investments Holdings LLC grew its position in Amylyx Pharmaceuticals by 88.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 28,785 shares of the company’s stock worth $55,000 after acquiring an additional 13,509 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $2,300,000. Renaissance Technologies LLC increased its holdings in shares of Amylyx Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 811,488 shares of the company’s stock valued at $1,542,000 after purchasing an additional 106,888 shares in the last quarter. Hsbc Holdings PLC raised its position in Amylyx Pharmaceuticals by 57.9% in the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after purchasing an additional 27,954 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $400,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Stock Down 4.9 %

Amylyx Pharmaceuticals stock opened at $3.87 on Monday. The company’s 50-day moving average price is $5.08 and its two-hundred day moving average price is $3.32. The stock has a market cap of $265.28 million, a P/E ratio of -1.01 and a beta of -0.68. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AMLX shares. Leerink Partners set a $4.00 target price on Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a report on Friday, October 18th. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Bank of America upgraded Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.